Thomas C. Harding

8.9k total citations
49 papers, 2.2k citations indexed

About

Thomas C. Harding is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Thomas C. Harding has authored 49 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 28 papers in Molecular Biology and 13 papers in Genetics. Recurrent topics in Thomas C. Harding's work include PARP inhibition in cancer therapy (17 papers), Virus-based gene therapy research (10 papers) and CRISPR and Genetic Engineering (7 papers). Thomas C. Harding is often cited by papers focused on PARP inhibition in cancer therapy (17 papers), Virus-based gene therapy research (10 papers) and CRISPR and Genetic Engineering (7 papers). Thomas C. Harding collaborates with scholars based in United States, United Kingdom and Australia. Thomas C. Harding's co-authors include Karin Jooss, Guang Huan Tu, Melinda VanRoey, Andrew D. Simmons, James B. Uney, Jianmin Fang, Kathryn Koprivnikar, Jingjing Qian, Bo Luan and Alshad S. Lalani and has published in prestigious journals such as Journal of Biological Chemistry, Nature Biotechnology and Cancer Research.

In The Last Decade

Thomas C. Harding

49 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas C. Harding United States 22 1.3k 951 585 527 245 49 2.2k
Yuuri Hashimoto Japan 24 834 0.6× 776 0.8× 568 1.0× 589 1.1× 370 1.5× 91 2.3k
Joan M. Robbins United States 21 1.3k 1.0× 442 0.5× 466 0.8× 716 1.4× 113 0.5× 49 2.6k
Nagesh Rao United States 26 1.3k 1.0× 400 0.4× 329 0.6× 304 0.6× 309 1.3× 74 2.3k
Neil P. Rodrigues United Kingdom 17 1.8k 1.4× 598 0.6× 278 0.5× 637 1.2× 133 0.5× 34 3.0k
Jeannette Bennicelli United States 21 1.9k 1.5× 446 0.5× 602 1.0× 296 0.6× 412 1.7× 31 2.5k
Magnus Essand Sweden 34 1.6k 1.2× 1.9k 2.0× 1.1k 1.9× 1.4k 2.6× 324 1.3× 124 4.1k
Martin Lenter Germany 26 1.6k 1.2× 879 0.9× 236 0.4× 599 1.1× 175 0.7× 44 3.1k
Laila Ritsma Netherlands 20 1.3k 1.0× 626 0.7× 176 0.3× 387 0.7× 213 0.9× 36 2.3k
Tomotsugu Ichikawa Japan 28 1.3k 1.0× 676 0.7× 1.1k 1.9× 214 0.4× 217 0.9× 96 2.8k
Christine A. Fargeas Germany 23 1.0k 0.8× 832 0.9× 151 0.3× 574 1.1× 195 0.8× 37 2.2k

Countries citing papers authored by Thomas C. Harding

Since Specialization
Citations

This map shows the geographic impact of Thomas C. Harding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas C. Harding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas C. Harding more than expected).

Fields of papers citing papers by Thomas C. Harding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas C. Harding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas C. Harding. The network helps show where Thomas C. Harding may publish in the future.

Co-authorship network of co-authors of Thomas C. Harding

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas C. Harding. A scholar is included among the top collaborators of Thomas C. Harding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas C. Harding. Thomas C. Harding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zboralski, Dirk, Frank Osterkamp, Aileen Hoehne, et al.. (2023). Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. European Journal of Nuclear Medicine and Molecular Imaging. 50(9). 2621–2635. 27 indexed citations
2.
Liao, Mingxiang, Heidi Giordano, Thomas C. Harding, et al.. (2022). Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. Clinical Pharmacokinetics. 61(11). 1477–1493. 8 indexed citations
3.
Hurley, Rachel M., Ksenija Nesic, Olga Kondrashova, et al.. (2018). Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance. 78(13). 1 indexed citations
4.
Zhao, Xin, Swati Kaushik, Kevin Lin, et al.. (2018). A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Reports. 23(3). 918–929. 30 indexed citations
5.
Helman, Elena, Minh Nguyen, Chris Karlovich, et al.. (2018). Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clinical Lung Cancer. 19(6). 518–530.e7. 52 indexed citations
6.
Nguyen, Minh, Liliane Robillard, Kevin Lin, Thomas C. Harding, & Andrew D. Simmons. (2018). Abstract 1716: The PARP inhibitor rucaparib activates the STING pathway and enhances antitumor responses of immune checkpoint inhibitors in BRCA deficient syngeneic models. Cancer Research. 78(13_Supplement). 1716–1716. 4 indexed citations
7.
Haringsma, Henry J., Andrew R. Allen, Thomas C. Harding, & Andrew D. Simmons. (2015). Abstract 3595: In vivo acquired resistance to the mutant EGFR inhibitor Rociletinib (CO-1686) is associated with activation of the c-MET pathway. Cancer Research. 75(15_Supplement). 3595–3595. 2 indexed citations
8.
9.
Smith, B. Douglas, Yvette L. Kasamon, Jeanne Kowalski, et al.. (2010). K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. Clinical Cancer Research. 16(1). 338–347. 77 indexed citations
10.
Tu, Guang Huan, et al.. (2010). Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunology Immunotherapy. 59(9). 1313–1323. 25 indexed citations
11.
Nguyen, Minh, et al.. (2007). Rapamycin-regulated Control of Antiangiogenic Tumor Therapy Following rAAV-mediated Gene Transfer. Molecular Therapy. 15(5). 912–920. 16 indexed citations
12.
Fang, Jianmin, Andrew D. Simmons, Guang Huan Tu, et al.. (2007). An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In Vivo. Molecular Therapy. 15(6). 1153–1159. 84 indexed citations
13.
Harding, Thomas C., et al.. (2006). Enhanced Gene Transfer Efficiency in the Murine Striatum and an Orthotopic Glioblastoma Tumor Model, Using AAV-7- and AAV-8-Pseudotyped Vectors. Human Gene Therapy. 17(8). 807–820. 36 indexed citations
14.
He, Yulong, Iiro Rajantie, Katri Pajusola, et al.. (2005). VEGFR-3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Research. 65. 474–474. 5 indexed citations
15.
Fang, Jianmin, Jingjing Qian, Thomas C. Harding, et al.. (2005). Stable antibody expression at therapeutic levels using the 2A peptide. Nature Biotechnology. 23(5). 584–590. 306 indexed citations
16.
Farson, Deborah, Thomas C. Harding, Jun Liu, et al.. (2004). Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectors. The Journal of Gene Medicine. 6(12). 1369–1381. 53 indexed citations
17.
Glover, Colin P., et al.. (2003). Long‐term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron‐specific promoters are used. The Journal of Gene Medicine. 5(7). 554–559. 27 indexed citations
18.
Harding, Thomas C., Luzheng Xue, Ali Bienemann, et al.. (2001). Inhibition of JNK by Overexpression of the JNK Binding Domain of JIP-1 Prevents Apoptosis in Sympathetic Neurons. Journal of Biological Chemistry. 276(7). 4531–4534. 101 indexed citations
19.
Beaucamp, Nicola, et al.. (1998). Overexpression of hsp70i facilitates reactivation of intracellular proteins in neurones and protects them from denaturing stress. FEBS Letters. 441(2). 215–219. 36 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuuri Hashimoto Breakdown of academic impact, for papers by Joan M. Robbins Breakdown of academic impact, for papers by Nagesh Rao Breakdown of academic impact, for papers by Neil P. Rodrigues Breakdown of academic impact, for papers by Jeannette Bennicelli Breakdown of academic impact, for papers by Magnus Essand Breakdown of academic impact, for papers by Martin Lenter Breakdown of academic impact, for papers by Laila Ritsma Breakdown of academic impact, for papers by Tomotsugu Ichikawa Breakdown of academic impact, for papers by Christine A. Fargeas
Rankless by CCL
2026